HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Liver Diseases (Liver Disease)

Subscribe to New Research on Liver Diseases

Pathological processes of the LIVER.

Also Known As:

Liver Disease; Diseases, Liver; Liver Dysfunction; Disease, Liver; Dysfunction, Liver; Dysfunctions, Liver; Liver Dysfunctions

Networked: 20937 relevant articles (888 outcomes, 2014 trials/studies) for this Disease, Comments

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Infection
2.	Fibrosis (Cirrhosis)
3.	Hepatocellular Carcinoma (Hepatoma)
4.	Hepatitis B
5.	Chronic Hepatitis B

Experts

1.	Trautwein, Christian: 22 articles (10/2012 - 04/2002)
2.	Manns, Michael P: 22 articles (02/2012 - 06/2002)
3.	Manns, M P: 18 articles (11/2012 - 04/2000)
4.	Mieli-Vergani, Giorgina: 17 articles (06/2012 - 01/2002)
5.	Tacke, Frank: 14 articles (10/2012 - 04/2002)
6.	Sata, Michio: 13 articles (12/2012 - 01/2002)
7.	Trauner, Michael: 13 articles (11/2012 - 11/2004)
8.	Vergani, Diego: 13 articles (08/2012 - 01/2002)
9.	Dhawan, Anil: 12 articles (11/2012 - 02/2002)
10.	Gershwin, M Eric: 12 articles (07/2010 - 05/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Liver Diseases:

1.	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 02/01/1994 - "Ursodeoxycholic acid has been reported to be beneficial for patients with various chronic cholestatic liver diseases. " 07/01/2012 - "Ursodeoxycholic acid (UDCA) is widely used for the treatment of liver dysfunction. " 02/01/2004 - "Ursodeoxycholic acid (UDCA) is widely used for the treatment of cholestatic liver diseases. " 02/01/2004 - "Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease." 09/24/1999 - "The therapeutic efficacy of ursodeoxycholic acid (UDCA) has been widely demonstrated in various liver diseases, suggesting that UDCA might protect hepatocytes against common mechanisms of liver damage. " Order ALL the reference details at left...
2.	InterferonsIBA 01/01/2001 - "The short courses of interferon monotherapy that were used in the early 1990s led to sustained improvement in liver disease and durable loss of detectable virus in fewer than 10% of patients. " 02/01/2000 - "Interferon monotherapy became clinically available 10 years ago but resulted in sustained improvement in liver disease and durable loss of detectable virus in fewer than 10% of treated patients. " 11/01/1995 - "Thus, longterm interferon treatment seems effective in clearing hepatitis C virus from serum of patients with chronic liver disease." 01/01/1990 - "These results indicate that interferon is effective in inducing clearance of HBV from serum and improvement of biochemical and histological parameters of liver disease. " 09/01/2003 - "In the absence of suitable animal models, HCV dynamic studies in man have been helpful in defining the mechanisms of action of interferon in chronic HCV liver disease. " Order ALL the reference details at left...
3.	Hepatitis B e AntigensIBA 10/01/2012 - "In a country with considerable amount of active CHB patients, monotherapy with a highly potent third generation drug has the most health-gain, and is cost-effective in both HBeAg-positive and negative in all stages of liver disease." 01/01/1995 - "We now show that the number of amino acid substitutions in the HBV core is low in viral sequences from patients with HBeAg positive chronic liver disease and HBeAg negative HBeAb positive patients in remission, but the frequency of substitutions is high in HBeAg, negative HBeAb positive patients with active liver disease. " 09/01/2006 - "Courses of finite duration, aiming to achieve sustained off-therapy responses, are practically restricted to HBeAg+ patients with compensated chronic liver disease, whereas long-term therapy aiming to achieve maintained on-therapy remission is mostly applicable to HBeAg- individuals either with early or advanced liver disease. " 07/01/1996 - "Conversely about 90% of children infected later in life clear HBeAg and achieve sustained remission of liver disease before reaching adulthood. " 03/01/2007 - "These will be followed eventually by HBeAg seroconversion, which is usually accompanied by remission of liver disease and confers favourable outcome. " Order ALL the reference details at left...
4.	Lamivudine (3TC)FDA Link 08/01/2000 - "A significant reduction was noted in the morbidity and hospitalizations for complications of liver disease before and after starting lamivudine (1.5+/-0.7 vs. 0.6+/-0.7, p<0.002). " 07/01/2000 - "Liver disease-significant improvement with lamivudine." 11/01/2002 - "Lamivudine has previously been found to be effective not only in patients with compensated liver disease due to hepatitis B virus (HBV) but also in those with hepatic decompensation. " 01/01/2008 - "However, liver dysfunction was not improved by lamivudine. " 07/01/2012 - "One patient developed decompensated liver disease owing to noncompliance to lamivudine therapy. " Order ALL the reference details at left...
5.	DNA (Deoxyribonucleic Acid)IBA 05/01/1997 - "The results show that in general, the branched DNA assay detects HBV DNA in more patients than hybrid-capture and that this improved detection rate is relevant clinically and genome equivalents/ml are preferred to pg/ml to quantify HBV DNA in clinical specimens and finally qualitative, non-quantitative polymerase chain reaction can detect HBV DNA in patients without evidence of active HBV-related liver disease. " 07/01/2000 - "No TTV infected child [follow-up: 31 (median; range: 6-60) months] showed signs of liver disease; five infants cleared TTV DNA after 22 (median; range: 6-60) months. " 04/01/1999 - "Advances in computer-aided diagnosis, imaging techniques, DNA mutation analysis, virology, immunology and biochemistry have improved our understanding of chronic liver diseases and the possibilities for non-invasive diagnosis. " 11/01/1998 - "Two patients cleared HBV DNA, and their liver disease improved by clinical and histologic criteria. " 11/27/1996 - "Our aim was to test its efficacy when used pre- and posttransplantation in HBV-DNA positive patients with endstage liver disease. " Order ALL the reference details at left...
6.	AntigensIBA 07/01/1990 - "All 21 cleared the antigen during follow-up and liver disease was either mild and asymptomatic (nine cases) or clinically overt (12 cases), but none had life-threatening liver disease. " 03/01/1993 - "Blast cells with Auer rods demonstrated 8;21 translocation lacking 11q with 30 of 30 analyzed bone marrow cells, and the following antigen pattern: CD5+, CD19+, CD33+, CD56+, HLA-DR+. After 4 courses of post remission therapy, the maintenance therapy was discontinued because of his liver dysfunction. " 04/01/1988 - "In several liver diseases qualitative and quantitative changes in the HLA gene product expression can be found on hepatocytes, bile duct epithelium and sinusoidal lining cells and these changes may affect the efficacy of the immune system in recognizing an exogenous antigen. " 05/01/1985 - "We postulate that, in patients with liver disease either increased intestinal uptake resulting in increased humoral response, or decreased hepatic clearance of food antigens intensifying a humoral response to these foreign antigens, may occur." 12/01/1976 - "While persistence of the antigenaemia is associated with persisting liver disease, the converse is not true in that the disappearance of the antigen does not necessarily imply an improvement in liver disease. " Order ALL the reference details at left...
7.	Hepatitis B Surface Antigens (HBsAg)FDA Link 05/01/1992 - "Although the frequency of HBsAg loss in treated patients is relatively low, the improvement in liver disease obtained from IFN therapy is sustained over a long period." 03/01/2006 - "Patients who on follow-up cleared HBsAg and/or did not develop any clinical, radiologic, or histologic evidence of chronic liver disease (CLD) were categorized as AVHB (group 1). " 05/01/2012 - "The present study reveals a low incidence of liver dysfunction in HBsAg-/HBcAb+ DLBCL patients, both in CHOP group and in R-CHOP group. " 09/01/2005 - "The purpose of the present study was to determine the frequency of hepatitis B virus (HBV) markers in families of HBsAg-positive patients with chronic liver disease. " 01/01/2002 - "The aim of the present study was to evaluate the clinical characteristics at first hospital consultation, according to the genotype of hepatitis B virus (HBV), in patients with chronic liver diseases and positivity for hepatitis B surface antigen (HBsAg) in metropolitan Tokyo. " Order ALL the reference details at left...
8.	Interferon-alpha (Interferon Alfa)FDA Link 04/01/1996 - "Efficacy of low-dose alpha interferon therapy in HBV-related chronic liver disease in Asian Indians: a randomized controlled trial." 03/01/1994 - "Treatment with alfa-interferon (alpha IFN) was added and thereafter, the liver dysfunction improved. " 07/07/2005 - "To study the expression of interferon-alpha/beta (IFN-alpha/beta) receptor protein in liver of patients with hepatitis C virus (HCV)-related chronic liver disease and its clinical significance. " 11/01/1998 - "In addition, 120 consecutive patients with chronic liver diseases (disease control group), who had never received alpha-interferon therapy, were evaluated during the period of the study (at least for 12 months). " 03/01/1992 - "The present study was carried out to test the hypothesis that the appearance of one or both of these markers signaled reactivation in chronic carriers with liver disease who were treated with alpha-interferon (IFN). " Order ALL the reference details at left...
9.	Biological Markers (Surrogate Marker)IBA 06/04/2012 - "There was a significant improvement in biochemical markers of liver disease following SVR (P< 0.001). " 01/05/2010 - "Based on this pilot study we conclude: (i) high urinary epsilondA-levels, reflecting massive LPO-derived DNA damage in vivo may contribute to the development of HCC; (ii) epsilondA-measurements in urine and target tissues should thus be further explored as a putative risk marker to follow malignant progression of inflammatory liver diseases in affected patients; (iii) etheno adducts may serve as biomarkers to assess the efficacy of (chemo-)preventive and therapeutic interventions." 01/01/2009 - "The development of non-invasive biomarkers, FibroTest-ActiTest in 2001 and more recently FibroMax, as well as transient elastography (TE) has changed the management of chronic liver disease. " 04/01/1996 - "Although widely used as a serum marker, frequent false-positive results in patients with benign liver disease, result in poor specificity. " 01/01/2010 - "This study showed that 2-D DIGE-based proteomic analysis of the plasma was helpful in screening for new plasma biomarkers for liver disease. " Order ALL the reference details at left...
10.	Ribavirin (Virazole)FDA LinkGeneric 01/01/2008 - "The study subjects were 1,193 patients with HCV-related chronic liver disease and IFN- or IFN plus ribavirin-induced SVR. " 05/01/2000 - "Single oral 600 mg doses of ribavirin were administered to healthy male and female volunteers (n = 6) and patients with stable chronic liver disease (n = 17), in a parallel group study. " 05/01/2000 - "The primary objective of this study was to describe the single dose pharmacokinetics of ribavirin in subjects with normal liver function and those with various degrees of stable chronic liver disease. " 02/01/2012 - "Over the last decade, treatment with peginterferon (PEG-IFN) plus ribavirin (RBV) has been recommended for coinfected patients who are at the greatest risk for liver disease; however, the effectiveness of HCV treatment in this population has been disappointing. " 08/01/2011 - "However, changes in FEV1 and FEV1/FVC can be observed in patients with advanced liver disease in the first 12 weeks of treatment with PEG-IFN and ribavirin." Order ALL the reference details at left...

Therapies and Procedures

1.	Liver Transplantation 07/01/2012 - "Liver transplantation, the best option for many end-stage liver diseases, is indicated in more candidates than the donor availability. " 09/01/2011 - "Liver transplantation is the best treatment for end stage liver diseases. " 06/27/2010 - "Sexual dysfunction in chronic liver disease: is liver transplantation an effective cure?" 04/27/2009 - "Liver transplantation is the best treatment option for endstage liver disease. " 01/01/2007 - "Liver transplantation has emerged as a highly effective treatment for patients with HCC, particularly in the setting of significant underlying liver disease. " Order ALL the reference details at left...
2.	Transplantation (Transplant Recipients) 07/01/2003 - "One year posttransplantation, follow-up data from transplant recipients showed significant improvement in most psychological domains relative to both healthy comparison participants and patients with chronic liver disease who did not undergo transplantation. " 01/01/2006 - "Successful cryopreservation of hepatocytes is essential to the future of hepatocyte transplantation as a treatment for liver disease, and also for the improved in vitro use of hepatocytes for research. " 06/15/2011 - "Mortality in those surviving beyond 1 year in UK liver transplant recipients was more than twice that expected in the general population and had not improved during the study period, independent of cause of liver disease, recipient age, recipient gender, and donor age. " 01/01/2010 - "Therapeutic efficacy of human hepatocyte transplantation in a SCID/uPA mouse model with inducible liver disease." 08/01/1996 - "This report suggests that TIPS may be feasible and effective for managing patients with life-threatening liver dysfunction after marrow transplantation." Order ALL the reference details at left...
3.	Drug Therapy (Chemotherapy) 02/01/2005 - "Although, severe liver dysfunction was observed, the patient achieved a complete remission (CR) on day 31 following chemotherapy and has maintained CR for more than five years. " 03/13/1998 - "Therapy with IFN-alpha for 9 weeks induced a remission in liver disease and complete remission of ML was obtained with subsequent chemotherapy. " 02/01/1989 - "It is difficult, time-consuming, and expensive to evaluate the therapeutic efficacy of regional chemotherapy of metastatic liver disease by means of imaging procedures. " 09/01/2012 - "RFA combined with chemotherapy is a promising treatment for NPC metastatic liver disease with improved local response, PFS, and OS compared to current chemotherapy protocols." 01/01/2009 - "Facial swelling and liver dysfunction improved immediately, and after five courses of chemotherapy, she achieved partial remission without any severe adverse events. " Order ALL the reference details at left...
4.	Transplants (Transplant) 08/01/2009 - "In animal models of metabolic liver disease, adopting strategies that provide a selective advantage for transplanted hepatocytes have proved to be highly effective in repopulating recipient livers, and the current relatively poor success rate of hepatocyte transplants in humans can be attributed to the lack of a clinically applicable procedure to induce a similar repopulation of the human liver. " 01/01/2009 - "In animal models of liver disease, adopting strategies to provide a selective advantage for transplanted hepatocytes has proved highly effective in repopulating recipient livers, but the poor success of today's hepatocyte transplants can be attributed to the lack of a clinically applicable procedure to force a similar repopulation of the human liver. " 12/01/2007 - "In animal models of liver disease, adopting strategies to provide a selective advantage for transplanted foetal or adult hepatocytes have proved highly effective in repopulating recipient livers, but the poor success of today's hepatocyte transplants can be attributed to the lack of a clinically applicable procedure to force a similar repopulation of the human liver. " 03/01/1996 - "Newer preservation solutions permit elective timing of the procedure and a clearer understanding of the natural history of the underlying liver disease has helped to define those patients most in need of a transplant earlier in the course of their illness. " 07/01/2006 - "Early referral of patients, especially in cases of TPN-liver disease, is mandatory to obtain good outcomes and avoid high mortality rates on the transplant waiting list. " Order ALL the reference details at left...
5.	Parenteral Nutrition 08/01/2004 - "Since then, the management of parenteral nutrition has improved so much that nowadays adolescents have a fair chance of surviving more than 15 to 20 years without severe liver disease. " 07/01/2006 - "A randomized, controlled trial is necessary to study the efficacy of this new approach to parenteral nutrition-associated liver disease." 01/01/2010 - "She was prohibited from eating for 10 days and treated with parenteral nutrition until liver dysfunction was improved. " 09/01/2009 - "The objective was to determine the safety and efficacy of a fish oil-based intravenous lipid emulsion (ILE) in the treatment of parenteral nutrition-associated liver disease (PNALD). " 03/01/2008 - "Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease." Order ALL the reference details at left...

blog comments powered by Disqus

TREATMENT OPTIONS
for Liver Diseases,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 888 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$24.95 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$490.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>